Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group

2020 ◽  
Vol 121 (8) ◽  
pp. 1201-1208 ◽  
Author(s):  
Charlotte M. Heidsma ◽  
Madison Hyer ◽  
Diamantis I. Tsilimigras ◽  
Flavio Rocha ◽  
Daniel E. Abbott ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Study Group ◽  
Pancreatic Neuroendocrine Tumors ◽  
Tumor Study ◽  
The Us ◽  
Tumor Study Group

Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group

2019 ◽  
Vol 26 (8) ◽  
pp. 2517-2524 ◽  
Author(s):  
Alexandra G. Lopez-Aguiar ◽  
Mohammad Y. Zaidi ◽  
Eliza W. Beal ◽  
Mary Dillhoff ◽  
John G. D. Cannon ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Study Group ◽  
Pancreatic Neuroendocrine Tumors ◽  
Tumor Study ◽  
The Us ◽  
Tumor Study Group

Defining the number of lymph nodes needed to accurately stage small bowel neuroendocrine tumors: An 8-institution study from the US neuroendocrine tumor study group.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 265-265
Author(s):  
Mohammad Zaidi ◽  
Alexandra G Lopez-Aguiar ◽  
Mary Dillhoff ◽  
Eliza W Beal ◽  
George A. Poultsides ◽  
...  
Keyword(s):  
Small Bowel ◽  
Lymph Nodes ◽  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Lymph Node Staging ◽  
Study Group ◽  
Curative Intent ◽  
Tumor Study ◽  
The Us ◽  
Tumor Study Group

265 Background: Small bowel neuroendocrine tumors (SB-NETs) frequently involve regional lymph nodes (LNs). The prognostic value of LN positivity on recurrence of disease is not well defined. The number of LNs needed to accurately stage patients is unknown. Methods: All patients with primary SB-NETs who underwent curative-intent resection at 8 institutions in the US Neuroendocrine Tumor Study Group between 2000 and 2016 were identified. Patients with distant metastatic disease were excluded. The association of LN positivity with recurrence of disease and the extent of lymphadenectomy required were analyzed. Results: Of 2182 patients with resected NETs, 203 had SB-NETs. Median age was 60 yrs, 56% were male, and median follow-up was 39 months. 83.5% of patients (n = 157) had LN positive disease. There was no difference in 3-year recurrence free survival (3-yr RFS) among patients with 1 or 2 positive LNs compared to patients with negative LNs (p = 0.63). Patients who had 3 or more positive LNs had a worse 3-yr RFS compared to those with 0, 1, or 2 positive LNs (n = 92 vs n = 73; 3-yr RFS 82% vs 92%; p < 0.001). Retrieval of 8 or more LNs was associated with a higher positive LN count compared to less than 8 LNs (4.6 vs. 1.6; p = 0.002). However, an increasing LN ratio was not associated with 3-yr RFS. When examining patients who had less than 8 lymph nodes retrieved, there was no difference in 3-yr RFS in those patients with 3 or more positive LNs compared to those with 0, 1, or 2 positive LNs (3-yr RFS: 100% vs 91%; p = 0.37). Retrieval of more than 8 lymph nodes, however, accurately discriminated patients with 3 or more positive LNs compared to those with 0, 1, or 2 positive LNs (3-yr RFS: 79.7% vs 93.5%; p = 0.005). Conclusions: For patients undergoing curative-intent resection of small bowel NETs, accurate lymph node staging requires a minimum of 8 lymph nodes for examination. 3 or more positive LNs is associated with decreased 3-yr RFS compared to 0, 1, or 2 positive lymph nodes. A thorough regional lymphadenectomy is critical for accurate staging and management of patients with small bowel neuroendocrine tumors.

scholarly journals The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8‐institution study from the US Neuroendocrine Tumor Study Group

2018 ◽  
Vol 119 (1) ◽  
pp. 5-11
Author(s):  
Mohammad Y. Zaidi ◽  
Alexandra G. Lopez‐Aguiar ◽  
George A. Poultsides ◽  
Mary Dillhoff ◽  
Flavio G. Rocha ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Neuroendocrine Tumors ◽  
Symptom Control ◽  
Study Group ◽  
Tumor Study ◽  
The Us ◽  
The Impact ◽  
Tumor Study Group

Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group

2019 ◽  
Vol 23 (11) ◽  
pp. 2225-2231 ◽  
Author(s):  
Apeksha Dave ◽  
Eliza W. Beal ◽  
Alexandra G. Lopez-Aguiar ◽  
George Poultsides ◽  
Eleftherios Makris ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Study Group ◽  
Risk Calculator ◽  
Acs Nsqip ◽  
Tumor Study ◽  
The Us ◽  
Tumor Study Group
Sign in / Sign up

Export Citation Format

Share Document